Lind Value II ApS Increases Position in Novo Nordisk A/S $NVO

Lind Value II ApS raised its position in shares of Novo Nordisk A/S (NYSE:NVO) by 255.2% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 299,144 shares of the company’s stock after purchasing an additional 214,919 shares during the quarter. Novo Nordisk A/S comprises 6.3% of Lind Value II ApS’s portfolio, making the stock its 6th largest holding. Lind Value II ApS’s holdings in Novo Nordisk A/S were worth $16,600,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the business. Jennison Associates LLC lifted its position in shares of Novo Nordisk A/S by 0.3% during the 2nd quarter. Jennison Associates LLC now owns 18,885,343 shares of the company’s stock valued at $1,303,466,000 after acquiring an additional 63,341 shares during the last quarter. Loomis Sayles & Co. L P boosted its position in shares of Novo Nordisk A/S by 1.5% in the 2nd quarter. Loomis Sayles & Co. L P now owns 12,576,031 shares of the company’s stock valued at $867,998,000 after purchasing an additional 187,789 shares during the period. Kingstone Capital Partners Texas LLC increased its stake in Novo Nordisk A/S by 301,443.6% in the 2nd quarter. Kingstone Capital Partners Texas LLC now owns 10,005,216 shares of the company’s stock worth $690,560,000 after purchasing an additional 10,001,898 shares in the last quarter. Sustainable Growth Advisers LP raised its holdings in Novo Nordisk A/S by 11.7% during the 2nd quarter. Sustainable Growth Advisers LP now owns 6,192,636 shares of the company’s stock worth $427,416,000 after buying an additional 649,390 shares during the period. Finally, State Street Corp lifted its stake in Novo Nordisk A/S by 0.8% during the second quarter. State Street Corp now owns 6,047,683 shares of the company’s stock valued at $418,231,000 after buying an additional 47,430 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Up 7.4%

Shares of NYSE:NVO opened at $51.66 on Wednesday. The company has a current ratio of 0.78, a quick ratio of 0.57 and a debt-to-equity ratio of 0.52. The stock has a market capitalization of $230.65 billion, a PE ratio of 15.02 and a beta of 0.67. Novo Nordisk A/S has a 1 year low of $43.08 and a 1 year high of $93.80. The firm has a fifty day moving average price of $49.55 and a 200 day moving average price of $57.16.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Wednesday, November 5th. The company reported $1.02 earnings per share for the quarter, topping analysts’ consensus estimates of $0.77 by $0.25. The company had revenue of $11.79 billion during the quarter, compared to analysts’ expectations of $11.98 billion. Novo Nordisk A/S had a return on equity of 73.50% and a net margin of 32.76%. Analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: FDA approval for oral Wegovy — first oral GLP‑1 for weight management, opening a much larger addressable market and giving Novo a product to sell in cash‑pay channels starting in early January. Novo Nordisk’s weight-loss pill wins FDA approval
• Positive Sentiment: First‑mover advantage vs. Lilly — being first to get an oral GLP‑1 in the U.S. may help Novo defend and regain market share versus Eli Lilly and attract investors betting on a revenue rebound. Shares in Wegovy-maker Novo Nordisk pop 6% after GLP-1 pill approval
• Positive Sentiment: Commercial plan and pricing — Novo plans an early‑January U.S. launch, targeting cash‑pay consumers with a $149/month introductory price, which could drive quick uptake outside of payer constraints. The FDA has approved the first GLP-1 pill for weight loss, clearing a tablet from Novo Nordisk
• Neutral Sentiment: Investor flows and derivatives activity — unusually large call buying and heavy media coverage pushed volatile trading and option activity, amplifying the move but also signaling short‑term momentum trading. Stock Market Today, Dec. 23: Novo Nordisk Surges After FDA Approves Oral Wegovy Weight Loss Pill
• Neutral Sentiment: Market & ETF interest — approval is drawing broader investor interest in GLP‑1 exposure via healthcare ETFs, which can benefit the sector while diluting idiosyncratic flows into any single name. Novo Nordisk’s Wegovy Pill Shakes Up Rivalry With Eli Lilly, Puts Health Care ETFs In Focus
• Negative Sentiment: Intense competition from Eli Lilly — Lilly remains a major rival with its own oral/injectable programs; analysts warn competition will intensify in 2026, capping pricing and share gains. Novo Nordisk Strikes First With Oral Wegovy — But Can It Outrun Lilly’s Looming Pill?
• Negative Sentiment: Regional pricing and generic risks — in markets like India, both Lilly and Novo are racing to secure positions before cheaper generics arrive next year, highlighting a risk of faster margin erosion in some geographies. Focus: Lilly, Novo lock horns in India’s obesity drug race

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the stock. Jefferies Financial Group assumed coverage on shares of Novo Nordisk A/S in a research report on Monday, October 27th. They set an “underperform” rating on the stock. Hsbc Global Res lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 24th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Novo Nordisk A/S in a research report on Monday. Rothschild Redb upgraded shares of Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a report on Tuesday, September 16th. Finally, Rothschild & Co Redburn raised shares of Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a research note on Tuesday, September 16th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, eleven have assigned a Hold rating and four have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $53.33.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.